<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596102</url>
  </required_header>
  <id_info>
    <org_study_id>IC51-303</org_study_id>
    <nct_id>NCT00596102</nct_id>
  </id_info>
  <brief_title>Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51</brief_title>
  <official_title>Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51. An Uncontrolled Phase 3 Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <brief_summary>
    <textblock>
      The study investigates the long term safety and immunogenicity of the Japanese Encephalitis
      vaccine IC51 up to month 60.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer (PRNT)</measure>
    <time_frame>24 months after the first vaccination</time_frame>
    <description>first vaccination refers to 1st vaccine administration in studies IC51-301 or IC51-302</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer (PRNT)</measure>
    <time_frame>6, 12, 36, 48 and 60 months after 1st vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers</measure>
    <time_frame>6, 12, 36, 48 and 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6, 12, 24, 36, 48 and 60 months after 1st vaccination</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">3258</enrollment>
  <condition>Japanese Encephalitis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese Encephalitis purified inactivated vaccine</intervention_name>
    <description>Japanese Encephalitis purified inactivated vaccine</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 3,300 subjects having completed IC51, JE-VAX or placebo treatment in studies
        IC51-301 or IC51-302 will take part in the safety follow up, up to month 6 after 1st
        vaccination in the study IC51-301 (NCT00604708) or IC51-302 (NCT00605085).

        Only ~160 subjects, who have been treated with IC51 will take part in the immunogenicity
        and long-term analysis up to month 60.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects at least 18 years of age

          -  Written informed consent obtained prior to study entry

          -  Subjects correctly included and having completed clinical studies IC51-301
             (NCT00604708) and IC51-302 (NCT00605085) with at least one vaccination

        Exclusion Criteria:

          -  Inability or unwillingness to provide informed consent and to abide the requirements
             of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelyn Hatzenbichler, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <results_first_submitted>November 14, 2013</results_first_submitted>
  <results_first_submitted_qc>June 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2014</results_first_posted>
  <last_update_submitted>June 27, 2014</last_update_submitted>
  <last_update_submitted_qc>June 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>study participants were recruited from 44 study centers previously participating in study IC51-301 and IC51-302</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>IC51</title>
          <description>no active treatment in study IC51-303, IC51 vaccinations were performed in preceeding study IC51-301 or IC51-302</description>
        </group>
        <group group_id="P2">
          <title>JE-VAX</title>
          <description>no active treatment in study IC51-303, vaccinations were performed in preceeding study IC51-301</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>no treatment in study IC51-303, vaccinations were performed in preceeding study IC51-302</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Up to Month 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2283"/>
                <participants group_id="P2" count="338"/>
                <participants group_id="P3" count="637"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2283"/>
                <participants group_id="P2" count="338"/>
                <participants group_id="P3" count="637"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Up to Month 60</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2283"/>
                <participants group_id="P2" count="338"/>
                <participants group_id="P3" count="637"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102">long-term safety follow-up beyond Month 6 for a sub-set of subjects in &quot;IC51&quot; group only</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2181"/>
                <participants group_id="P2" count="338"/>
                <participants group_id="P3" count="637"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IC51</title>
          <description>no active treatment in study IC51-303, IC51 vaccinations were performed in preceeding study IC51-301 or IC51-302</description>
        </group>
        <group group_id="B2">
          <title>JE-VAX</title>
          <description>no active treatment in study IC51-303, vaccinations were performed in preceeding study IC51-301</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>no treatment in study IC51-303, vaccinations were performed in preceeding study IC51-302</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2283"/>
            <count group_id="B2" value="338"/>
            <count group_id="B3" value="637"/>
            <count group_id="B4" value="3258"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" spread="13.8"/>
                    <measurement group_id="B2" value="42.3" spread="14.1"/>
                    <measurement group_id="B3" value="33.5" spread="13.0"/>
                    <measurement group_id="B4" value="35.6" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1274"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="365"/>
                    <measurement group_id="B4" value="1840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1009"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="272"/>
                    <measurement group_id="B4" value="1418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2076"/>
                    <measurement group_id="B2" value="288"/>
                    <measurement group_id="B3" value="574"/>
                    <measurement group_id="B4" value="2938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer (PRNT)</title>
        <description>first vaccination refers to 1st vaccine administration in studies IC51-301 or IC51-302</description>
        <time_frame>24 months after the first vaccination</time_frame>
        <population>subjects enrolled into this study who planned to participate in the long-term immunogenicity part and received IC51 in the respective preceeding study</population>
        <group_list>
          <group group_id="O1">
            <title>IC51</title>
            <description>no active treatment in study IC51-303, IC51 vaccinations were performed in preceeding study IC51-301 or IC51-302</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer (PRNT)</title>
          <description>first vaccination refers to 1st vaccine administration in studies IC51-301 or IC51-302</description>
          <population>subjects enrolled into this study who planned to participate in the long-term immunogenicity part and received IC51 in the respective preceeding study</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="75.7" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer (PRNT)</title>
        <time_frame>6, 12, 36, 48 and 60 months after 1st vaccination</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers</title>
        <time_frame>6, 12, 36, 48 and 60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <time_frame>6, 12, 24, 36, 48 and 60 months after 1st vaccination</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>all participants across all treatment groups were followed-up until Month 6; a sub-group of the IC51 treatment arm was followed-up until Month 60</time_frame>
      <desc>group &quot;IC51 Month 6&quot; includes the sub-set of study participants that later on is followed-up until Month 60 (group &quot;IC51 Month 60&quot;)</desc>
      <group_list>
        <group group_id="E1">
          <title>IC51 Month 6</title>
          <description>no active treatment in study IC51-303, IC51 vaccinations were performed in preceeding study IC51-301 or IC51-302; follow-up till Month 6</description>
        </group>
        <group group_id="E2">
          <title>JE-VAX</title>
          <description>no active treatment in study IC51-303, JE-VAX vaccinations were performed in preceeding study IC51-301 or IC51-302; follow-up till Month 6</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>no active treatment in study IC51-303, Plarcebo vaccinations were performed in preceeding study IC51-301 or IC51-302; follow-up till Month 6</description>
        </group>
        <group group_id="E4">
          <title>IC51 Month 60</title>
          <description>no active treatment in study IC51-303, IC51 vaccinations were performed in preceeding study IC51-301 or IC51-302; follow-up till Month 60</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Appendix Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendiceal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Abscess Soft Tissue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Joint Ligament Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Tibia Fructure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Smear Cervix Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Synovial Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Shoulder Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Toe Deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarinoma Pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central Nervous System Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Post Herpetic Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Urethral Stricture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mediastinal Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nasal Septum Deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Blood Donor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Meniscus Operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Acute Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Herpes Simplex</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Shoulder Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dental Implantation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katrin Dubischar-Kastner</name_or_title>
      <organization>Valneva Austria GmbH</organization>
      <phone>+43 1 20620 ext 0</phone>
      <email>info@valneva.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

